Key result
Enoxaparin, nadroparin, and dalteparin significantly increased TFPI levels compared to baseline during hemodialysis (P < 10(-4)), with enoxaparin providing the most potent short-term stimulus.
Why the study?
Do different low-molecular-weight heparins (enoxaparin, nadroparin, dalteparin) have varying effects on plasma TFPI and hemostatic factors during hemodialysis in maintenance HD patients?
Population
21 patients on maintenance hemodialysis
Comparison
Enoxaparin, nadroparin, and dalteparin… vs Active comparators
Design
RCT, Randomized crossover study in 6 groups (Latin-square design)
Follow-up
3 periods of 2 months each
Authors
Loading...
Enoxaparin may be favored to maximize short-term TFPI release in HD; extends comparative RCT data on LMWH-specific endothelial effects.
RCT (n=21)
Crossover (Latin-square design)
Do different low-molecular-weight heparins (enoxaparin, nadroparin, dalteparin) have varying effects on plasma TFPI and hemostatic factors during hemodialysis in maintenance HD patients?
p-value: p=< 10(-4)
Enoxaparin provides the most potent short-term stimulus for endothelial TFPI release during hemodialysis compared to nadroparin and dalteparin, though long-term baseline levels remain unaffected.
Naumnik et al. (2010) conducted an RCT in Maintenance hemodialysis (n=21). Enoxaparin, nadroparin, and dalteparin vs. Active comparators (crossover design) was evaluated on Plasma levels of total TFPI, PDGF-AB, and PF 1 + 2 (p=< 10(-4)). Enoxaparin, nadroparin, and dalteparin significantly increased TFPI levels compared to baseline during hemodialysis (P < 10(-4)), with enoxaparin providing the most potent short-term stimulus.